Cargando…
Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals
BACKGROUND: The relationship between inflammatory bowel disease (IBD) and the risk of Parkinson’s Disease (PD) has been investigated in several epidemiological studies. However, the results of these studies were inconclusive and inconsistent. We evaluated the potential relationship between IBD and P...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157095/ https://www.ncbi.nlm.nih.gov/pubmed/37153103 http://dx.doi.org/10.3389/fmed.2023.1137366 |
_version_ | 1785036674194997248 |
---|---|
author | Li, Hong-xing Zhang, Cui Zhang, Kai Liu, Yi-zhe Peng, Xiao-xiao Zong, Qiang |
author_facet | Li, Hong-xing Zhang, Cui Zhang, Kai Liu, Yi-zhe Peng, Xiao-xiao Zong, Qiang |
author_sort | Li, Hong-xing |
collection | PubMed |
description | BACKGROUND: The relationship between inflammatory bowel disease (IBD) and the risk of Parkinson’s Disease (PD) has been investigated in several epidemiological studies. However, the results of these studies were inconclusive and inconsistent. We evaluated the potential relationship between IBD and PD risk by a meta-analysis. METHODS: Search the electronic databases PubMed, Embase and Cochrane databases from inception to November 30, 2022, to identify relevant studies that assess the risk of PD in patients with IBD. The cohort, cross-sectional, mendelian randomization and case-control studies that reported risk estimates of PD and IBD were included in our analysis. The random-effect model and fixed-effects model were used to calculate the summary relative risks (RRs) with 95% confidence intervals (CIs). RESULTS: In total, 14 studies (nine cohort studies, two cross-sectional studies, two mendelian randomization studies and one case-control study) involving more than 13.4 million individuals were analyzed in our analysis. Our results suggested that the risk of PD in IBD patients is moderately increased, with the pooled RR was 1.17 (95% CI: 1.03–1.33, P = 0.019). Omit of any single study from this analysis had little effect on the combined risk estimate. No evidence of publication bias was found. In the subgroup analysis, the combined RR was 1.04 (95% CI: 0.96, 1.12, P = 0.311) for Crohn’s disease (CD), and 1.18 (95% CI: 1.06, 1.31, P = 0.002) for ulcerative colitis (UC). In addition, a significant association was identified in patients with IBD aged ≥ 60 years (RR = 1.22; 95% CI: 1.06–1.41, P = 0.007), but not in age < 60 years (RR = 1.19; 95% CI: 0.58–2.41, P = 0.639). Meanwhile, the meta-analysis results suggested a protective role for IBD medication use against PD development, with the RR was 0.88 (95% CI: 0.74, 1.04, P = 0.126). CONCLUSION: Our results indicated that patients with IBD had a moderately higher risk of PD compared to non-IBD individuals. Patients with IBD should be aware of the potential risks for PD, especially who were ≥ 60 years old. |
format | Online Article Text |
id | pubmed-10157095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101570952023-05-05 Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals Li, Hong-xing Zhang, Cui Zhang, Kai Liu, Yi-zhe Peng, Xiao-xiao Zong, Qiang Front Med (Lausanne) Medicine BACKGROUND: The relationship between inflammatory bowel disease (IBD) and the risk of Parkinson’s Disease (PD) has been investigated in several epidemiological studies. However, the results of these studies were inconclusive and inconsistent. We evaluated the potential relationship between IBD and PD risk by a meta-analysis. METHODS: Search the electronic databases PubMed, Embase and Cochrane databases from inception to November 30, 2022, to identify relevant studies that assess the risk of PD in patients with IBD. The cohort, cross-sectional, mendelian randomization and case-control studies that reported risk estimates of PD and IBD were included in our analysis. The random-effect model and fixed-effects model were used to calculate the summary relative risks (RRs) with 95% confidence intervals (CIs). RESULTS: In total, 14 studies (nine cohort studies, two cross-sectional studies, two mendelian randomization studies and one case-control study) involving more than 13.4 million individuals were analyzed in our analysis. Our results suggested that the risk of PD in IBD patients is moderately increased, with the pooled RR was 1.17 (95% CI: 1.03–1.33, P = 0.019). Omit of any single study from this analysis had little effect on the combined risk estimate. No evidence of publication bias was found. In the subgroup analysis, the combined RR was 1.04 (95% CI: 0.96, 1.12, P = 0.311) for Crohn’s disease (CD), and 1.18 (95% CI: 1.06, 1.31, P = 0.002) for ulcerative colitis (UC). In addition, a significant association was identified in patients with IBD aged ≥ 60 years (RR = 1.22; 95% CI: 1.06–1.41, P = 0.007), but not in age < 60 years (RR = 1.19; 95% CI: 0.58–2.41, P = 0.639). Meanwhile, the meta-analysis results suggested a protective role for IBD medication use against PD development, with the RR was 0.88 (95% CI: 0.74, 1.04, P = 0.126). CONCLUSION: Our results indicated that patients with IBD had a moderately higher risk of PD compared to non-IBD individuals. Patients with IBD should be aware of the potential risks for PD, especially who were ≥ 60 years old. Frontiers Media S.A. 2023-04-20 /pmc/articles/PMC10157095/ /pubmed/37153103 http://dx.doi.org/10.3389/fmed.2023.1137366 Text en Copyright © 2023 Li, Zhang, Zhang, Liu, Peng and Zong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Li, Hong-xing Zhang, Cui Zhang, Kai Liu, Yi-zhe Peng, Xiao-xiao Zong, Qiang Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals |
title | Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals |
title_full | Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals |
title_fullStr | Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals |
title_full_unstemmed | Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals |
title_short | Inflammatory bowel disease and risk of Parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals |
title_sort | inflammatory bowel disease and risk of parkinson’s disease: evidence from a meta-analysis of 14 studies involving more than 13.4 million individuals |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157095/ https://www.ncbi.nlm.nih.gov/pubmed/37153103 http://dx.doi.org/10.3389/fmed.2023.1137366 |
work_keys_str_mv | AT lihongxing inflammatoryboweldiseaseandriskofparkinsonsdiseaseevidencefromametaanalysisof14studiesinvolvingmorethan134millionindividuals AT zhangcui inflammatoryboweldiseaseandriskofparkinsonsdiseaseevidencefromametaanalysisof14studiesinvolvingmorethan134millionindividuals AT zhangkai inflammatoryboweldiseaseandriskofparkinsonsdiseaseevidencefromametaanalysisof14studiesinvolvingmorethan134millionindividuals AT liuyizhe inflammatoryboweldiseaseandriskofparkinsonsdiseaseevidencefromametaanalysisof14studiesinvolvingmorethan134millionindividuals AT pengxiaoxiao inflammatoryboweldiseaseandriskofparkinsonsdiseaseevidencefromametaanalysisof14studiesinvolvingmorethan134millionindividuals AT zongqiang inflammatoryboweldiseaseandriskofparkinsonsdiseaseevidencefromametaanalysisof14studiesinvolvingmorethan134millionindividuals |